ACST | Acasti Pharma Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.20 - 3.45
52 Week Range	1.9800 - 3.60
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	27,682
Average Volume	33,247
Shares Outstanding	10,139,900
Market Cap	34,171,463
Sector	Healthcare
Industry	Biotechnology
IPO Date	2012-02-07

Valuation
Profitability
Growth
Health
P/E Ratio	-2.36
Forward P/E Ratio	N/A
EPS	-1.43
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	32
Country	Canada
Website	ACST

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.

ACST's peers: ABVC, IBIO, ITRM, JAGX, OGEN, PTN, TNXP

*Chart delayed

Analyzing fundamentals for ACST we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see ACST Fundamentals page.

Watching at ACST technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ACST Technicals page.